PATENT CLAIM ANALYSIS

Application Number: 16025519
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-02
Patent Classification: ["544", "279000"]

Abstract:
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

Claim (Index 94):
A method of treating cancer in a patient comprising administering to said patient a therapeutically effective amount of 2\u2032-(2,6-difluoro-3,5-dimethoxyphenyl)-6\u2032-[(2-morpholin-4-ylethyl)amino]-1\u2032,2\u2032-dihydro-3\u2032H-spiro[cyclopropane-1,4\u2032-[2,7]naphthyridin]-3\u2032-one, or a pharmaceutically acceptable salt thereof, wherein said cancer is selected from bladder cancer, breast cancer, endometrial cancer, gastric cancer, lung cancer, non-small cell lung cancer, adenocarcinoma, multiple myeloma, myeloproliferative neoplasms (MPN), esophageal cancer, head and neck cancer, glioblastoma, ovarian cancer, cervical cancer, liver cancer, and kidney cancer.

Metadata:
- Claim Count in Document: 61.0
- Percentile: 95.0
- Lexical Diversity: 1.19355
- Patent Class: 544.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15408768', '15358371', '14256438', '14132653', '13915775']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7029967048136975
- 35 USC 102 Novelty (BERT): 0.4864256686958615
- Combined Prediction Score: 0.6813396012019138
- Mean Citation Score: 230.63026
- Max Citation Score: 238.27563
- Similarity Product: 200.51065737803228

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test